Iraj Daizadeh PhD MBA
Global Head, Regulatory Affairs (GRA), Innovative Medicines
Greater Boston · 1 connectionNot on Unlinked · Imported profile. Is this you? Claim it
Is this about you? Request removal
About
Iraj Daizadeh, PhD, MBA, is the Global Head of Regulatory Affairs (GRA) for Development (Brands/Innovative Medicines/Biosimilars) at Sun Pharmaceuticals. His current work is to build a cross-discipline, worldwide regulatory and quality team suitable to support a mid-to-large pharmaceutical company portfolio comprised of inline (Ilumya, Leqselvi, Winlevi, Cequa, Odomzo, Yonza, Absorbica, Levulan, Xelpos, Sezaby, Unloxcyt) and pipeline of small and large molecule assets across rare (orphan) and common rheumatology/immunology, oncology, dermatology, gastrointestinal, ophthalmology, neurology, and internal medicine (e.g., obesity/T2D) indications. His team successfully led Sun’s first original global marketing authorization for an innovative medicine (Leqselvi), and business development/due diligence/alliance management efforts (e.g., Checkpoint Pharmaceutics, Checkpoint Therapeutics). Prior to Sun, at Takeda, he was the VP/Head, GRA, Rare Diseases (Genetics, Immunology and Hematology), where his team successfully led two original global marketing application approvals (Livtencity and Adzynma) and met various inline (Trintellix, Takhzyro, Vonvendi, Natpara, Advate, Adynovate) and pipel
Experience
Jan 2020 to Jan 2023
Jan 2016 to Jan 2020
Jan 2013 to Jan 2015
Jan 2008 to Jan 2013
Jan 2004 to Jan 2007
Jan 2000 to Jan 2004
Education
Judge Business School - Master of Business Administration (MBA): Strategy
Judge Business School - Master of Business Administration (MBA): Strategy
Postdoctoral Fellow: Laboratory of Nobel Laureate Wally Gilbert, Theoretical and Computational Biology
Doctor of Philosophy (Ph.D.): Laboratory of Professor A. A. Stuchebrukhov, Theoretical and Computational Chemistry